Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium by Rami S. Komrokji, Najla H Al Ali, David Sallman, Eric Padron, Amy E. DeZern, John Barnard, Gail J. Roboz, Guillermo Garcia‐Manero, Alan List, David P. Steensma, Mikkael A. Sekeres

Get full text

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients by Abhishek A. Mangaonkar, Terra L. Lasho, Rhett P. Ketterling, Kaaren K. Reichard, Naseema Gangat, Aref Al-Kali, Kebede H. Begna, Animesh Pardanani, Najla H. Al Ali, Chetasi Talati, David Sallman, Eric Padron, Mrinal M. Patnaik, Ayalew Tefferi, Rami Komrokji

Get full text

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis by Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Panagiotis Katsonis, Koji Sasaki, Caleb A. Class, Elias Jabbour, David Sallman, Anthony Michael Hunter, Christopher Benton, Kelly S. Chien, Rajyalakshmi Luthra, Carlos E. Bueso-Ramos, Tapan Kadia, Michael Andreeff, Rami S. Komrokji, Najla H Al Ali, Nicholas Short, Naval Daver, Mark J. Routbort, Joseph D. Khoury, Keyur Patel, Irene Ganan-Gomez, Yue Wei, Gautam Borthakur, Farhad Ravandi, Kim-Anh Do, Kelly A. Soltysiak, Olivier Lichtarge, L. Jeffrey Medeiros, Hagop Kantarjian, Guillermo Garcia-Manero

Get full text